drugset / Trial / NCT04905407
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RandomizedParallel-groupOpen-labelTreatment
Summary
Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short. Tamibarotene is being studied as a treatment for participants with AML whose cancer has a specific genetic abnormality characterized by the overexpression of the retinoic acid receptor alpha (RARA) gene. This genetic profile is found in about 3 of every 10 people with AML. During the trial, tamibarotene will be given with 2 other drugs that are already used together to treat people who have AML and who cannot start treatment with standard chemotherapy.
Timeline
- Start
- 2021-08-26
- Primary completion
- 2024-08-12
- Completion
- 2024-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tamibarotene | Small molecule | 6 mg | Oral |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Venetoclax | Small molecule | 400 mg | Oral |